Developing
Biosimilars and CAR-T Cell pharmaceuticals

Driving significant cost reductions of key treatments for Leukemia, Multiple Sclerosis, age related vision loss and many other.

Learn more about BioCure

What is a Biosimilar medicine?

A medicine developed to be similar to an already existing and approved medicine which patent has expired and therefore can be sold at significantly lower prices.

Biosimilars are driven by a social agenda to make key life-saving drugs affordable to the general public.

Biosimilars Vs. Generic medicines

Generic medicines are also developed as copies of pharmaceuticals with expired patents.

Unlike Biosimilars, Generic drugs are based on Chemicals or  Small Molecules based active ingredients which are easy to synthesize and formulate with vast knowhow available in public domain.

Biosimilars are based on Large and Complex Molecules from Living Organisms (instead of chemicals) and cannot readily be synthesized by chemical means.

Such medicines (known as Biological drugs) are developed under significant trade secrets, have very little information in public domain and require significant knowhow and scientific skill to achieve successful replication.

Biological drugs  are extremely expensive for patients due to high development and manufacturing costs and can reach hundreds of thousands of dollars per specific treatment for one patient.

Due to the high costs of Biological drugs:

20% of patients choose to skip a dose every other month.

Cancer patients are 2.5 times more likely to file for bankruptcy.

30% of patients are completely drained from their savings.

Millions cannot afford even to start treatment at any.

level Fred Hutchinson, Cancer Research Center – Seattle USA  

CAR-T Cell Therapy

A novel scientific approach focused on “programming” patient’s own immune cells to identify and destroy cancer cells

First implementation of CAR-T wasin identification and destruction of Leukemia cancer cells.

2017, Emily Whitehead (USA), was the first Leukemia patient treated with CAR-T cell therapy. She was completely cured with total remission.

October 16,2018

BIOCURE ANNOUNCED a BREAKTHROUGH PRE-CLINICAL TRIAL RESULTS FOR CAR-T CELLS TREATMENT OF ACUTE LEUKEMIA

Trial results demonstrated zero toxicity of the reengineered BioCure CAR-T Cells within 7 and 28 days from their injection into mice.

CAR-T Cells therapy represent the most advanced scientific methods and biggest hope for millions of people suffering from cancer

Our Social Agenda

Affordable Key Pharmaceuticals

Patent expiration of major Biological drugs during the coming years creates an early market opportunities for Biosimilars.

Our agenda is to provide as many Biosimilar products as possible to leverage BioCure unique scientific knowhow and skills to drive social equality via affordable medicines.

Our Main Products

Acute Lymphoblastic Leukemia

CAR-T Cell Therapy

Clinical
2019
Commercial
2020

Multiple Sclerosis (MS)

Interferon Beta

Clinical
2020
Commercial
2021

Age related vision loss

Ranibizumab

Clinical
2020
Commercial
2021

Chemotherapy Effects Treatment

PEG-Filgrastim

Clinical
2021
Commercial
2022

Social Pharmaceuticals